Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 85 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cachexia; Cancer Clear all
Terminated Not applicable Interventional Results available

Multimodal Treatment Strategy for Cancer Cachexia

NCT00625742
View directory record Official record
Conditions
Advanced Cancer, Cachexia
Interventions
Graded Resistance Training, Aerobic Exercise, Melatonin, Juven, Atenolol, Ibuprofen
Behavioral · Drug · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Sep 3, 2026, 7:23 AM EDT
Completed No phase listed Observational

Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II

NCT01694602
View directory record Official record
Conditions
Cachexia
Interventions
(non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 3, 2026, 7:23 AM EDT
Terminated Phase 3 Interventional Results available

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

NCT01132547
View directory record Official record
Conditions
Cancer
Interventions
cyproheptadine hydrochloride, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
Long Beach, California • Hartford, Connecticut • Wilmington, Delaware + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 3, 2026, 7:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients

NCT00994669
View directory record Official record
Conditions
Cachexia
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
30 Years to 85 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 3, 2026, 7:23 AM EDT
Recruiting No phase listed Observational

Understanding New Cachexia Subtypes Through Observational Epidemiological Research

NCT07776353
View directory record Official record
Conditions
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Electronic health record review, Medical Device Usage and Evaluation, Physical functions assessments, Positron Emission Tomography (PET), Survey Administration
Procedure · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 3, 2026, 7:23 AM EDT
Recruiting No phase listed Observational

Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)

NCT06721260
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 3, 2026, 7:23 AM EDT
Completed Not applicable Interventional

Ultrasound in Evaluating Muscle-Glycogen Content in Cancer Patients

NCT03982082
View directory record Official record
Conditions
Cachexia, Malignant Solid Neoplasm
Interventions
Physical Therapy, Questionnaire Administration, Ultrasound
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 3, 2026, 7:23 AM EDT
Completed Phase 2 Interventional

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

NCT00066248
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Sep 3, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

NCT01433263
View directory record Official record
Conditions
Cachexia
Interventions
BYM338 active drug, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Tucson, Arizona • Tampa, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Sep 3, 2026, 7:23 AM EDT
Terminated Phase 2Phase 3 Interventional

Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia

NCT00127387
View directory record Official record
Conditions
Lung Cancer, Prostate Cancer, Neoplasm Metastasis, Bone Cancer
Interventions
Enbrel
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Sep 3, 2026, 7:23 AM EDT
Completed Phase 3 Interventional Results available

Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients

NCT00513357
View directory record Official record
Conditions
Gastrointestinal Cancer, Lung Cancer
Interventions
Melatonin, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Sep 3, 2026, 7:23 AM EDT
Completed Phase 1Phase 2 Interventional

Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss

NCT00003077
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
omega-3 fatty acid
Dietary Supplement
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
5
States / cities
Wilmington, Delaware • Iowa City, Iowa • Manhasset, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 3, 2026, 7:23 AM EDT
Completed Phase 2 Interventional

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.

NCT00267358
View directory record Official record
Conditions
Cancer Cachexia
Interventions
RC-1291 HCl, Placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
19
States / cities
Glendale, Arizona • Bakersfield, California • Encinitas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2013 · Synced Sep 3, 2026, 7:23 AM EDT
Terminated Phase 2 Interventional Results available

The Role of Ghrelin in Cancer Cachexia

NCT01505764
View directory record Official record
Conditions
Cancer Cachexia
Interventions
Anamorelin HCl, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 3, 2026, 7:23 AM EDT
Completed Phase 2 Interventional

Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss

NCT00004912
View directory record Official record
Conditions
Cachexia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
megestrol acetate, physical therapy
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
6
States / cities
North Little Rock, Arkansas • Long Beach, California • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2012 · Synced Sep 3, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

NCT05546476
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite, Fatigue, Cachexia
Interventions
ponsegromab, Placebo for ponsegromab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Conway, Arkansas • Little Rock, Arkansas • North Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 3, 2026, 7:23 AM EDT
Completed Phase 1 Interventional Results available

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

NCT04803305
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Ovarian Cancer, Loss of Appetite, Fatigue, Cachexia, Anorexia
Interventions
PF-06946860, Placebo for PF-06946860
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
32
States / cities
Little Rock, Arkansas • Beverly Hills, California • Camarillo, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 3, 2026, 7:23 AM EDT
Terminated Phase 2 Interventional Results available

Anamorelin Study for Advanced Pancreatic Cancer

NCT04844970
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Anamorelin Hydrochloride, Placebo
Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 3, 2026, 7:23 AM EDT
Completed Phase 1 Interventional

Low Antioxidant Diet in Controlling Cachexia in Patients With Oropharyngeal Cancer Receiving Chemotherapy and Radiation Therapy

NCT00486304
View directory record Official record
Conditions
Cachexia, Head and Neck Cancer, Weight Changes
Interventions
ADD, Placebo
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Sep 3, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia

NCT01614990
View directory record Official record
Conditions
Cancer Cachexia
Interventions
Macimorelin, Placebo
Drug
Lead sponsor
Garcia, Jose M., MD, PhD
Individual
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 3, 2026, 7:23 AM EDT
Recruiting Phase 2 Interventional

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

NCT05705492
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Gastric Carcinoma, Metastatic Colorectal Carcinoma (mCRC), Advanced Lung Carcinoma, Locally Advanced Hepatocellular Carcinoma
Interventions
Olanzapine, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 3, 2026, 7:23 AM EDT
Completed Not applicable Interventional

The Effects of a 12 Week Home-based Exercise Intervention on Physical Performance in Patients With Cancers of the Gastrointestinal Tract With Pre- Cachexia or Cachexia

NCT04802486
View directory record Official record
Conditions
Cachexia, Weight Loss, Gastrointestinal Cancer
Interventions
EXCAP©®
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 3, 2026, 7:23 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

NCT01355484
View directory record Official record
Conditions
Muscle Wasting, Non Small Cell Lung Cancer
Interventions
GTx-024, placebo
Drug
Lead sponsor
GTx
Industry
Eligibility
30 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Long Beach, California • Aventura, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Sep 3, 2026, 7:23 AM EDT
Completed Phase 2 Interventional

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia

NCT00378131
View directory record Official record
Conditions
Cancer Cachexia
Interventions
RC-1291, placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
17
States / cities
Glendale, Arizona • Encinitas, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2013 · Synced Sep 3, 2026, 7:23 AM EDT